Tone mix
Week by week 52 weeks
Share of Spyre Therapeutics, Inc. Common Stock's 135 headlines over the last 52 weeks by the model's call, and the same mix week by week.
Biggest swings in the last year
The weeks whose tone moved furthest from the 8-week average, with the story most outlets carried that week.
- Week of Sep 7, 2026 · tone +95Spyre Therapeutics Reports Positive Phase 2 SPY003 Data In Ulcerative Colitis+96
- Week of Aug 10, 2026 · tone +99Spyre Therapeutics Announces Grants of Inducement Awards+79
- Week of Jul 6, 2026 · tone +99Spyre Therapeutics Announces Grants of Inducement Awards+66
- Week of Nov 17, 2025 · tone +100Spyre Therapeutics (SYRE) Announces Positive Results for Phase 1 Study of SPY003+66
- Week of Aug 17, 2026 · tone -50Wall Street Zen Downgrades Spyre Therapeutics (NASDAQ:SYRE) to Sell-66
- Week of Jan 19, 2026 · tone +100Wall Street Bullish on Spyre Therapeutics, Inc. (SYRE) with Strong Buy Rating+62
Daily headline tone, last 90 sessions
Hover a session for its totals; click to pin.
Each point is the average score of the headlines about Spyre Therapeutics, Inc. Common Stock in one trading session, with the 8-session average drawn through it. Sessions with no headline about the company have no point.
Tone by period
Show the table · 3 rows, 3 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Last 7 sessions | 0 | No headlines |
| Last 30 sessions | 12 | +8 |
| Last 90 sessions | 41 | +4 |
No matching rows. Clear the filter to see all records.
Every headline in the period counts equally.
Headlines on Monday, October 19, 2026
2 headlines, average tone 0: 0 positive, 2 neutral and 0 negative. Showing all 2.
- www.themarketsdaily.com · 1 outletFinancial Review: Intellia Therapeutics (NASDAQ:NTLA) versus Spyre Therapeutics (NASDAQ:SYRE)Neutral
- www.manilatimes.net · 1 outletSpyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026Neutral
Show the table · 2 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Financial Review: Intellia Therapeutics (NASDAQ:NTLA) versus Spyre Therapeutics (NASDAQ:SYRE) | www.themarketsdaily.com | 1 | Neutral |
| Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026 | www.manilatimes.net | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Wednesday, October 14, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.dailypolitical.com · 1 outletAnalysts' Recent Ratings Updates for Spyre Therapeutics (SYRE)Neutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Analysts' Recent Ratings Updates for Spyre Therapeutics (SYRE) | www.dailypolitical.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Monday, October 12, 2026
1 headline, average tone +99: 1 positive, 0 neutral and 0 negative. Showing all 1.
- www.themarketsdaily.com · 1 outletSpyre Therapeutics, Inc. (NASDAQ:SYRE) Stock Has Consensus Target Price of $109.71 According to AnalystsPositive
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Spyre Therapeutics, Inc. (NASDAQ:SYRE) Stock Has Consensus Target Price of $109.71 According to Analysts | www.themarketsdaily.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Wednesday, October 7, 2026
1 headline, average tone -100: 0 positive, 0 neutral and 1 negative. Showing all 1.
- www.ibtimes.com.au · 1 outletSpyre Therapeutics Shares Fall 13 Percent to $81 After Pricing a $350 Million Stock Offering at $85 a ShareNegative
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Spyre Therapeutics Shares Fall 13 Percent to $81 After Pricing a $350 Million Stock Offering at $85 a Share | www.ibtimes.com.au | 1 | Negative |
No matching rows. Clear the filter to see all records.
Headlines on Tuesday, October 6, 2026
3 headlines, average tone 0: 0 positive, 3 neutral and 0 negative. Showing all 3.
- seekingalpha.com · 1 outletSpyre Therapeutics prices $350M public offering at $85 per shareNeutral
- www.manilatimes.net · 1 outletSpyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common StockNeutral
- www.manilatimes.net · 1 outletSpyre Therapeutics Announces Proposed Public Offering of its Common StockNeutral
Show the table · 3 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Spyre Therapeutics prices $350M public offering at $85 per share | seekingalpha.com | 1 | Neutral |
| Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock | www.manilatimes.net | 1 | Neutral |
| Spyre Therapeutics Announces Proposed Public Offering of its Common Stock | www.manilatimes.net | 1 | Neutral |
No matching rows. Clear the filter to see all records.
How the score works
A headline's tone is not a forecast of the share price. Read the headlines themselves before acting on an average.
Which headlines count
Headlines come from the GDELT global news feed from 2019-09-23 on. A headline counts only when a model judges it to be about Spyre Therapeutics, Inc. Common Stock, not a passing mention.
How each headline is scored
The model calls each headline positive, neutral or negative news for the company. A period's tone is the share of positive minus negative headlines, from -100 (all negative) to +100 (all positive).
When a headline counts
Headlines published by 9:15 a.m. New York time belong to that day's session. Later and weekend headlines move to the next trading session.
Repeated stories
When several outlets carry the same headline, it counts once per session.